Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
Kevin E. Kip, Erin K McCreary, Kevin Collins, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 4, pp. 496-504
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review
Alberto Boretti
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes
Brian E. McGarry, Benjamin D. Sommers, Andrew D. Wilcock, et al.
JAMA (2023) Vol. 330, Iss. 6, pp. 561-561
Open Access | Times Cited: 16
Project NextGen: Developing the Next Generation of Coronavirus Disease 2019 (COVID-19) Vaccines and Therapeutics to Respond to the Present and Prepare for the Future
Kimberly A. Hofmeyer, Christy L. Ventura, Kimberly L. Armstrong, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 115-121
Open Access | Times Cited: 3
Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2
Ziwei Wang, Amelia Siqi Huang, Lingfang Tang, et al.
Lab on a Chip (2024) Vol. 24, Iss. 4, pp. 642-657
Open Access | Times Cited: 2
Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors
Viviana De Luca, Andrea Angeli, Alessio Nocentini, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 971-971
Open Access | Times Cited: 2
A Short Update on the Use of Monoclonal Antibodies in COVID-19
Antonio Vitiello, Michela Sabbatucci, Annarita Ponzo, et al.
The AAPS Journal (2024) Vol. 26, Iss. 2
Closed Access | Times Cited: 2
Is LDL cholesterol associated with long-term mortality among primary prevention adults? A retrospective cohort study from a large healthcare system
Kevin E. Kip, David M. Diamond, Suresh Mulukutla, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e077949-e077949
Open Access | Times Cited: 2
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 2
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records
Christopher F. Bell, Daniel C. Gibbons, Myriam Drysdale, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304822-e0304822
Open Access | Times Cited: 2
Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial
Bruno Maranda, Sébastien M. Labbé, Magali Lurquin, et al.
The Lancet Infectious Diseases (2023)
Closed Access | Times Cited: 7
Phase II Study of Bemnifosbuvir in High-Risk Participants in a Hospital Setting with Moderate COVID-19
Arantxa Horga, Daniel R. Kuritzkes, John J. Kowalczyk, et al.
Future Virology (2023) Vol. 18, Iss. 8, pp. 489-500
Open Access | Times Cited: 6
Interface‐Guided Computational Protein Design Reveals Bebtelovimab‐Resistance Mutations in SARS‐CoV‐2 RBD: Correlation with Global Viral Genomes and Bebtelovimab‐Escape Mutations
Shweata Maurya, S Rajesh Kumar, Aditya K. Padhi
ChemistrySelect (2023) Vol. 8, Iss. 46
Closed Access | Times Cited: 6
Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
Margherita Passariello, Speranza Esposito, Lorenzo Manna, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10053-10053
Open Access | Times Cited: 3
Deep generative models predict SARS-CoV-2 Spike infectivity and foreshadow neutralizing antibody escape
Noor Youssef, Sarah F. Gurev, Fadi Ghantous, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies
Gavin C. Barnard, Michelle Zhou, Amy Shen, et al.
Biotechnology Progress (2023) Vol. 40, Iss. 1
Closed Access | Times Cited: 3
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions
Raymund R. Razonable
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 7, pp. 619-631
Closed Access | Times Cited: 2
COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
Serap Şimşek Yavuz
Infectious Diseases and Clinical Microbiology (2023) Vol. 5, Iss. 3, pp. 165-187
Open Access | Times Cited: 2
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Christopher F. Bell, Priyanka Bobbili, Raj Desai, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 3, pp. 183-198
Open Access
Outcomes of Monoclonal Antibody Use in Patients with COVID-19 (Preprint)
Jack Huber, Deanna Schnitzer, Hend Barry, et al.
(2024)
Open Access
Vitamin D supplementation and calcium: many-faced gods or nobody in fighting against Corona Virus Disease 2019
Azam Roohi, Soheila Gharagozlou
Clinical Nutrition ESPEN (2024) Vol. 62, pp. 172-184
Closed Access
Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants
Alfred Anzalone, William H. Beasley, Kimberly Murray, et al.
The Journal of Rural Health (2024)
Open Access
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
Nan Shang, Xianlin Li, Zhiyu Guo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort
Alessandro Soria, Francesca Graziano, Giulia Irene Ghilardi, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e36102-e36102
Open Access
Clinical practice guideline supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: Experience of a quaternary care centre
K. Hammond, François Bourdeau, Marina Klein, et al.
Journal of the Association of Medical Microbiology and Infectious Disease Canada (2024)
Closed Access
Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience
Nicola Perrotta, Luigi Angelo Fiorito, Cristiana Leanza, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113101-113101
Open Access
Page 1 - Next Page

Scroll to top